NSE: EMAMILTD | BSE: 531162

Falling Comet

Download real time

522.15 1.80 (0.35%)

New 52W Low in past week

613.9K NSE+BSE Volume

NSE 17 Nov, 2025 3:31 PM (IST)

22,791.8

Market Cap

Above industry Median

0.6

Beta 1Year

Very Low volatility

Emami Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for EMAMILTD, BSE:531162 Emami Ltd.

Emami Ltd.

13 Feb 2022

522.15

0.35%

Emami

Buy: Emami Ltd.

Khambatta Securities

Promoters unpledged 0.52% of shares in last quarter. Total pledge stands at 9.98% of promoter holdings

Emami Ltd.

03 Feb 2022

522.15

0.35%

EMAMI LTD

Accumulate: Emami Ltd.

Prabhudas Lilladhar

Navratna therapy, Kesh King onion range, Crme 21 products, however it will have any significant impact in a few years only. Although inflation in LLP and Rice bran oil remains high, 3-4% price increase and cost control will enable Emami prevent any significant margin erosion. We estimate 12% PAT CAGR over FY22-24 and value the stock at 30xDec23 EPS and assign a value of Rs624/share. We believe Rs1.6bn buyback (Max...

Emami Ltd. has an average target of 675.80 from 5 brokers.

Emami Ltd.

02 Nov 2021

522.15

0.35%

EARNINGS UPDATE- EMAMI 2QFY22

Buy: Emami Ltd.

Recommendation Target

Chola Wealth Direct

Background: Emami is a FMCG company with niche focus on relatively under penetrated segments such as antiseptic cream, fairness cream, talcum powder, cooling oil, pain balm and pain reliever. Emami's power brands such as Navratna Oil, Boroplus Cream, Zandu & MenthoPlus Balm, Fair & Handsome, Boroplus Powder, Navratna Cool Talc, Fast Relief, SonaChandi & Zandu accounts for 75% of company's sales. Emami sales have grown at a CAGR of 38.5% (FY2010-20)....

Number of FII/FPI investors decreased from 349 to 304 in Sep 2025 qtr

Emami Ltd.

30 Oct 2021

522.15

0.35%

Margin to come under pressure, but sales traction to continue

Buy: Emami Ltd.

Target

Motilal Oswal

HMN's 2QFY22 sales were in line with our expectations. Domestic sales/ volumes grew 9%/6.2% YoY. With a pickup in the pace of vaccination and diminishing fears of a severe third COVID wave, Healthcare grew only 5% YoY. Nevertheless, the segment was still up 26% on a two-year CAGR basis. On a positive note, revival in mobility led to double-digit growth in discretionary categories BoroPlus, Kesh King, and Male Grooming. While there has been some recent moderation in rural demand, its fundamentals are intact. The outlook for winter demand is positive....

Emami Ltd. is trading below all available SMAs

Emami Ltd.

29 Oct 2021

522.15

0.35%

Q2FY22 Result Update - Risk reward favorable on early winter Onset - ACCUMULATE

Accumulate: Emami Ltd.

Recommendation Target

Prabhudas Lilladhar

immunity boosters and higher base of balms in the base year even as Male Boroplus soft showing positive response and will be scaled up. (Rs23mn) led by MTM gain on certain investments in startups. Domestic Grooming, Boroplus, Kesh King and 7 oils in 1 did well. We believe Boroplus,...

Promoters unpledged 0.52% of shares in last quarter. Total pledge stands at 9.98% of promoter holdings

Emami Ltd.

11 Aug 2021

522.15

0.35%

EARNINGS UPDATE- EMAMI 1QFY22

Neutral: Emami Ltd.

Recommendation Target

Chola Wealth Direct

Prabhudas Lilladhar decreased Accumulate price target of Emami Ltd. to 608.0 on 10 Nov, 2025.

Emami Ltd.

02 Aug 2021

522.15

0.35%

Margin outlook getting better; sales recovery key to re-rating

Buy: Emami Ltd.

Target

Motilal Oswal

Emami (HMN)'s 1QFY22 sales were in line with expectations. Domestic sales grew 5% v/s 1QFY20 levels. While Healthcare and Pain Management have nearly doubled over 1QFY20 levels, the impact of the second COVID wave led lockdown resulted in sharp decline over 1QFY20 in Navratna (in the crucial summer season) and Male Grooming. The outlook for the domestic business gradually improved in Jun'21 and Jul'21, after modest growth over a two-year period in 1QFY22. This was partly offset by slower growth in the International business (~12% of sales)...

Promoters unpledged 0.52% of shares in last quarter. Total pledge stands at 9.98% of promoter holdings

Emami Ltd.

26 May 2021

522.15

0.35%

EARNINGS UPDATE- EMAMI 4QFY21

Buy: Emami Ltd.

Target

Chola Wealth Direct

Number of FII/FPI investors decreased from 349 to 304 in Sep 2025 qtr

Emami Ltd.

29 Jan 2021

522.15

0.35%

EARNINGS UPDATE- EMAMI 3QFY21

Buy: Emami Ltd.

Recommendation Target

Chola Wealth Direct

Promoters unpledged 0.52% of shares in last quarter. Total pledge stands at 9.98% of promoter holdings

Emami Ltd.

27 Jan 2021

522.15

0.35%

Record high margin; good near term sales outlook

Buy: Emami Ltd.

Target

Motilal Oswal

While HMN's sales/volume growth at 15%/13% were healthy, they were below our expectations. However, record high EBITDA margin led to beat on our EBITDA and PAT forecasts. Near term outlook remains healthy for the Herbal portfolio as well as rural growth. This would elevate HMN's topline growth above the disappointing growth levels of ~3.7% in the five years ended FY20. The management has also guided for ~30% EBITDA margin going forward....

Emami Ltd. has an average target of 675.80 from 5 brokers.

Is Emami Ltd. worth buying?

229 Votes:

Buy 74.24%

Sell 17.47%

Hold 8.3%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf